MISSISSAUGA, Ontario — Valeant Pharmaceuticals' former SVP and corporate controller has been appointed to the role of interim CFO.
Philip Loberg immediately replaces the drug maker's current CFO, Peggy Mulligan. The company has initiated a search to identify a permanent replacement.
Loberg joined Valeant in 2000 as treasurer and was appointed CFO of North America in 2006. In 2007, he was appointed to his most recent role of SVP, group financial controller. In that role, he was responsible for the upgrading and retooling of the global finance department following restructurings and the disposition of nonperforming assets.